Daiichi Sankyo Gains U.S. Diabetes Indication For Cholesterol Drug WelChol
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo received U.S. FDA sNDA approval for its cholesterol drug WelChol (colesevelam) as an adjunct therapy to improve glycemic control in patients with type 2 diabetes Jan. 18